- Report
- April 2025
- 175 Pages
Global
From €3959EUR$4,490USD£3,436GBP
- Report
- March 2025
- 200 Pages
Global
From €2195EUR$2,490USD£1,905GBP
- Clinical Trials
- April 2025
- 90 Pages
Global
From €1763EUR$2,000USD£1,531GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €1102EUR$1,250USD£957GBP
- Report
- October 2024
- 237 Pages
Global
From €7009EUR$7,950USD£6,084GBP
- Report
- October 2024
- 244 Pages
Global
From €7009EUR$7,950USD£6,084GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1323EUR$1,500USD£1,148GBP
- Report
- March 2018
- 174 Pages
Global
From €2425EUR$2,750USD£2,104GBP
- Report
- May 2024
- 137 Pages
Global
From €5730EUR$6,499USD£4,973GBP
- Report
- May 2024
- 139 Pages
Global
From €5730EUR$6,499USD£4,973GBP
- Report
- August 2023
- 74 Pages
Canada
From €2623EUR$2,975USD£2,277GBP
€3086EUR$3,500USD£2,678GBP
- Report
- June 2024
- 200 Pages
Global
From €7009EUR$7,950USD£6,084GBP
- Report
- August 2023
- 166 Pages
Global
From €6613EUR$7,500USD£5,739GBP
- Report
- February 2023
- 220 Pages
Global
From €6613EUR$7,500USD£5,739GBP
- Report
- October 2022
- 63 Pages
Global
From €1763EUR$2,000USD£1,531GBP
- Report
- October 2022
- 210 Pages
Global
From €1763EUR$2,000USD£1,531GBP

Repatha is a cardiovascular drug used to reduce the risk of heart attack and stroke in adults with certain conditions. It is a monoclonal antibody that works by blocking a protein called PCSK9, which helps regulate the amount of cholesterol in the blood. Repatha is used in combination with diet and exercise to reduce the risk of cardiovascular events in adults with established cardiovascular disease, or those at high risk of cardiovascular events due to familial hypercholesterolemia. It is also used to reduce the risk of cardiovascular events in adults with type 2 diabetes and atherosclerotic cardiovascular disease.
The Repatha market is highly competitive, with several major pharmaceutical companies offering the drug. These include Amgen, Sanofi, Regeneron, and Pfizer. Other companies, such as Merck, are also developing PCSK9 inhibitors, which could potentially compete with Repatha in the future. Show Less Read more